Abstract
Summary
Postmenopausal women with osteoporotic fracture (OF) had higher plasma dipeptidyl-peptidase 4 (DPP4) levels than those without. Furthermore, higher plasma DPP4 levels were significantly associated with higher bone turnover and a higher prevalence of OF. These results indicated that DPP4 may be associated with OF by mediating bone turnover rate.
Introduction
Evidence indicates that dipeptidyl-peptidase 4 (DPP4) plays a distinct role in bone metabolism. However, there has been no report on the association, if any, between circulating DPP4 levels and osteoporosis-related phenotypes, including osteoporotic fracture (OF). Therefore, we performed a case-control study to investigate these associations in postmenopausal women.
Methods
This study was conducted in multiple centers in Korea. We enrolled 178 cases with OF and 178 age- and body mass index-matched controls. OF was assessed by an interviewer-assisted questionnaire and lateral thoracolumbar radiographs. Bone turnover markers (BTMs), bone mineral density (BMD), and plasma DPP4 levels were obtained in all subjects.
Results
After adjustment for potential confounders, subjects with OF had significantly higher DPP4 levels than those without (P = 0.021). Higher DPP4 levels were significantly positively associated with higher levels of all BTMs, but not with BMD at all measured sites. The differences in DPP4 levels according to OF status disappeared after an additional adjustment for each BTM, but not after adjustment for any BMD values. BTMs explained approximately half of the relationship between DPP4 and OF. The risk of OF was 3.80-fold (95% confidence interval = 1.53–9.42) higher in subjects in the highest DPP4 quartile than in those in the lowest quartile after adjustment for potential confounders, including femoral neck BMD.
Conclusions
DPP4 may be associated with OF by at least partly mediating the bone turnover rate. Circulating DPP4 levels may be a potential biomarker that could increase the predictive power of current fracture risk assessment models.
References
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 17(12):1726–1733. doi:10.1007/s00198-006-0172-4
Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90(5):2787–2793. doi:10.1210/jc.2004-1568
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 19(4):385–397. doi:10.1007/s00198-007-0543-5
Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P (2010) Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 25(5):1002–1009. doi:10.1002/jbmr.12
Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD (2011) Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 152(2):457–467. doi:10.1210/en.2010-1098
Monami M, Dicembrini I, Antenore A, Mannucci E (2011) Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 34(11):2474–2476. doi:10.2337/dc11-1099
Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. European journal of biochemistry / FEBS 214(3):829–835
Nuche-Berenguer B, Portal-Nunez S, Moreno P, Gonzalez N, Acitores A, Lopez-Herradon A, Esbrit P, Valverde I, Villanueva-Penacarrillo ML (2010) Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 225(2):585–592. doi:10.1002/jcp.22243
Kim JY, Lee SK, Jo KJ, Song DY, Lim DM, Park KY, Bonewald LF, Kim BJ (2013) Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci 92(10):533–540. doi:10.1016/j.lfs.2013.01.001
Sanz C, Vazquez P, Blazquez C, Barrio PA, Alvarez Mdel M, Blazquez E (2010) Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Phys Endocrinol Metab 298(3):E634–E643. doi:10.1152/ajpendo.00460.2009
Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G, Garel JM (1996) Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett 393(2–3):248–252
Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, Hu J, He G, Luo X (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 28(7):1641–1652. doi:10.1002/jbmr.1898
Epitacio-Pereira CC, Silva GM, Salvatori R, Santana JA, Pereira FA, Gois-Junior MB, Britto AV, Oliveira CR, Souza AH, Santos EG, Campos VC, Pereira RM, Valenca EH, Barbosa RA, Farias MI, de Paula FJ, Ribeiro TV, Oliveira MC, Aguiar-Oliveira MH (2013) Isolated GH deficiency due to a GHRH receptor mutation causes hip joint problems and genu valgum, and reduces size but not density of trabecular and mixed bone. J Clin Endocrinol Metab 98(11):E1710–E1715. doi:10.1210/jc.2013-2349
Somm E, Bonnet N, Martinez A, Marks PM, Cadd VA, Elliott M, Toulotte A, Ferrari SL, Rizzoli R, Huppi PS, Harper E, Melmed S, Jones R, Aubert ML (2012) A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest 122(9):3295–3306. doi:10.1172/jci63232
Hanski C, Huhle T, Gossrau R, Reutter W (1988) Direct evidence for the binding of rat liver DPP IV to collagen in vitro. Exp Cell Res 178(1):64–72
Bermpohl F, Loster K, Reutter W, Baum O (1998) Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens. FEBS Lett 428(3):152–156
Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C (2003) Role of gastrointestinal hormones in postprandial reduction of bone resorption. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 18(12):2180–2189. doi:10.1359/jbmr.2003.18.12.2180
Wang L, Zhao R, Shi X, Wei T, Halloran BP, Clark DJ, Jacobs CR, Kingery WS (2009) Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro. Bone 45(2):309–320. doi:10.1016/j.bone.2009.04.203
Hou JM, Wu M, Lin QM, Lin F, Xue Y, Lan XH, Chen EY, Wang ML, Yang HY, Wang FX (2014) Lactoferrin promote primary rat osteoblast proliferation and differentiation via up-regulation of insulin-like growth factor-1 expression. Mol Biol Rep 41(8):5019–5030. doi:10.1007/s11033-014-3368-2
Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD (2006) Role of IGF-I signaling in regulating osteoclastogenesis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 21(9):1350–1358. doi:10.1359/jbmr.060610
Burns DM, Forstrom JM, Friday KE, Howard GA, Roos BA (1989) Procalcitonin’s amino-terminal cleavage peptide is a bone-cell mitogen. Proc Natl Acad Sci U S A 86(23):9519–9523
Kiel D (1995) Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 10(4):518–523. doi:10.1002/jbmr.5650100403
Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 8(9):1137–1148. doi:10.1002/jbmr.5650080915
Covey MK, Smith DL, Berry JK, Hacker ED (2008) Importance of cross-calibration when replacing DXA scanners: QDR4500W and discovery Wi. J Nurs Meas 16(3):155–170
Moon DH, Lee HK, Shin JW, Kim JS, Jo JM, Kim GS, Kim SW (1999) Cross-calibration of bone mineral density between two different dual x-ray absorptiometry systems: Hologic QDR4500-A and Lunar EXPERT-XL. The Korean journal of nuclear medicine 33(3):282–288
Choi YJ, Lee BJ, Kim HJ, Kim DJ, Lee KW, Chung YS (2008) Cross-calibration of GE lunar expert and GE lunar prodigy advance for bone mineral density measurements. Osteoporosis 6(1):23–32
Bahk J, Yun SC, Kim YM, Khang YH (2015) Impact of unintended pregnancy on maternal mental health: a causal analysis using follow up data of the panel study on Korean children (PSKC). BMC pregnancy and childbirth 15:85. doi:10.1186/s12884-015-0505-4
Dobnig H, Piswanger-Solkner JC, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Riedmuller G, Brueck C, Fahrleitner-Pammer A (2007) Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 92(5):1678–1686. doi:10.1210/jc.2006-2079
van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG (2004) Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 350(20):2033–2041. doi:10.1056/NEJMoa032546
Pena JM, Aspberg S, MacFadyen J, Glynn RJ, Solomon DH, Ridker PM (2015) Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern Med 175(2):171–177. doi:10.1001/jamainternmed.2014.6388
Rousseau JC, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P (2014) Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab 99(7):2533–2539. doi:10.1210/jc.2013-3893
Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA (2012) High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for osteoporosis research study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 27(12):2592–2602. doi:10.1002/jbmr.1718
Kim BJ, Koh JM, Lee SY, Lee YS, Lee SH, Lim KH, Cho EH, Kim SW, Kim TH, Kim SY, Kim GS (2012) Plasma sphingosine 1-phosphate levels and the risk of vertebral fracture in postmenopausal women. J Clin Endocrinol Metab 97(10):3807–3814. doi:10.1210/jc.2012-2346
Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 24(2):489–494. doi:10.1007/s00198-012-1978-x
Koutkia P, Canavan B, Breu J, Grinspoon S (2005) Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J Clin Endocrinol Metab 90(4):2154–2160. doi:10.1210/jc.2004-1466
Dreyer P, Vieira JG (2010) Bone turnover assessment: a good surrogate marker? Arquivos brasileiros de endocrinologia e metabologia 54(2):99–105
Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH (2014) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-205216
Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47(11):1663–1670
Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, Kang SH, Park DB, Oh BC, Kim J, Heo ST, Koh G, Lee DH (2013) CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 98(6):2553–2561. doi:10.1210/jc.2012-4288
Zheng T, Yang L, Liu Y, Liu H, Yu J, Zhang X, Qin S (2015) Plasma DPP4 activities are associated with osteoporosis in postmenopausal women with normal glucose tolerance. J Clin Endocrinol Metab 100(10):3862–3870. doi:10.1210/jc.2015-223
Wewer Albrechtsen NJ, Bak MJ, Hartmann B, Christensen LW, Kuhre RE, Deacon CF, Holst JJ (2015) Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocrine connections 4(1):50–57. doi:10.1530/ec-14-0126
Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC (2002) Whole blood cryopreservation in epidemiological studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 11(11):1496–1498
Acknowledgments
This study was supported by grants from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (project nos. HI13C1432 and HI14C2258) and from Takeda Pharmaceuticals Korea Co., Ltd., Seoul, Republic of Korea. The sponsor did not participate in the study design, the data collection and analysis, the writing of the manuscript, or in the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest
None.
Additional information
Hyeonmok Kim and Ki Hyun Baek contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kim, H., Baek, K.H., Lee, SY. et al. Association of circulating dipeptidyl-peptidase 4 levels with osteoporotic fracture in postmenopausal women. Osteoporos Int 28, 1099–1108 (2017). https://doi.org/10.1007/s00198-016-3839-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-016-3839-5